Introduction
============

Myocardial remodeling and fibrosis after heart failure are associated with increased mast cell density, and mast-cell deficient mice show an improved prognosis following myocardial infarction ([@B30]). Pharmacological stabilization of mast cells also reduces the impairment of heart function in animal models ([@B63]). Chymase, a heparin-bound serine protease with chymotrypsin-like activity, is one of the major components of cardiac mast cell granules. Mouse chymases include mouse mast cell protease (mMCP)-1, -4, -5, and -9. ([@B13]). The closest mouse analog to human chymase, in terms of localization, substrate specificity and storage properties is mMCP-4 ([@B44]). Furthermore, chymase activity in the mouse heart is primarily due to mMCP-4 expression ([@B18]). Cardiovascular targets of chymase in mice and humans include the activation of angiotensin-II (Ang-II), endothelin-1 (ET-1) and matrix metalloproteinase 9 (MMP-9) as well as the degradation of the matrix protein fibronectin ([@B2]; [@B18]; [@B50]; [@B5]).

Chymase is rapidly secreted from mast cells after acute myocardial infarction (AMI) ([@B10]) and is upregulated in the infarcted region of human hearts ([@B6]). Laine and colleagues also showed that the number of chymase-containing mast cells increases in the adventitia of coronary vessels of the infarcted region of human hearts ([@B28]). In heart failure models, such as permanent myocardial infarction (PMI) in the hamster, chymase inhibitors improve the cardiac function and survival, whether these molecules are used alone or in combination with an angiotensin-converting enzyme inhibitor ([@B16]; [@B21]). Chymase inhibition also reduced lethal arrhythmia 8 h after myocardial infarction in dogs, similarly to an angiotensin receptor antagonist, and reduces cardiomyofibrillar loss in a mitral regurgitation model of heart failure in this animal model ([@B20]; [@B43]). All these studies focused on the angiotensin-II (Ang-II)-producing activities of chymase, while Pat and colleagues further demonstrated chymase-dependent fibronectin degradation ([@B43]). Oyamada and colleagues also reported a reduction in active MMP-9 and infarcted area after chymase inhibition in a swine model of ischemia-reperfusion ([@B42]). On the other hand, Kanemitsu and colleagues also showed a beneficial action of chymase inhibition in a rat model of PMI, in which the action of chymase is thought to be Ang-II-independent, implying a transforming growth factor-β mechanism ([@B24]). In mouse settings, chymase inhibition reduces left ventricular remodeling in a model of heart failure caused by intermittent hypoxia ([@B34]).

The expression of mMCP-4 is increased after PMI in mice ([@B37]). Its genetic repression improves ventricular remodeling after ischemia-reperfusion injury ([@B59]). This effect was shown to be independent from Ang-II system blockade and the authors suggested an insulin-like growth factor-1 (IGF-1), a previously unknown chymase substrate, dependent pathway ([@B59]). ET-1 is also a major factor involved in myocardial infarction pathophysiology and is a critical factor in pulmonary hypertension, a possible complication of heart failure ([@B46]). Finally our group demonstrated the role of mMCP-4 in the endogenous pulmonary synthesis of ET-1 *in vivo* ([@B18]). Therefore, in light of the beneficial role of chymase inhibitors in other rodent models of heart failure, we hereby hypothesized that specific mMCP-4 activity repression would protect mice from PMI. We demonstrate in the present study the profound impact of the genetic repression of mMCP-4 in mice subjected to irreversible left anterior descending (LAD) coronary artery ligation.

Materials and Methods {#s1}
=====================

Additional description is available in the **[Supplementary Methods](#SM2){ref-type="supplementary-material"}** section.

Animals
-------

C57BL/6J mice were purchased from Charles River (Montréal, QC, Canada) and housed in our facilities. Genitor mMCP-4 KO mice from the same background were generated by homologous recombination in embryonic stem cells as previously reported ([@B58]) and bred in our facilities. Their homozygous genotypes were confirmed previously by our group ([@B18]). All animals were kept at constant room temperature (RT; 23°C) and humidity (78%) under a controlled light/dark cycle (6:00 AM--6:00 PM), with standard chow and tap water available *ad libitum*. Animal care and experiments were approved by the Ethics Committee on Animal Research of the University of Sherbrooke following the Canadian Council on Animal Care guidelines ([@B3]) and the Guide for the Care and Use of Laboratory Animals of the United States National Institutes of Health ([@B36]).

Animal Protocol
---------------

Four-month old male mice were anesthetized with a mixture of ketamine and xylazine (87/13 mg/kg, intra-muscular) and intubated to install assisted breathing. An incision was performed between the third and fourth ribs to access the LAD coronary artery. The pericardium was opened, and then PMI was induced when the LAD artery was ligated using 8-0 silk suture (Ethicon, Johnson & Johnson, Markham, ON, Canada) 2 mm from the atrium, and the costal cavity was then closed with 6-0 silk suture (Ethicon). SHAM surgery consisted in passing the suture under the LAD artery without ligating. Immediately after surgery, buprenorphine (0.1 mg/kg, subcutaneous) was administered for post-surgical pain management and subsequently added every 8 h for 24 h. The mice were distributed in four groups: wild-type (WT) SHAM, WT PMI, mMCP-4 KO SHAM, and mMCP-4 KO PMI. The mice were then monitored for 1 day (six mice per group) or 3 days (*n*: 15 WT SHAM, 12 mMCP-4 KO SHAM, 13 WT PMI, and 13 mMCP-4 KO PMI) or 7 days (*n*: 8 WT SHAM, 8 mMCP-4 KO SHAM, 8 WT PMI, and 8 mMCP-4 KO PMI). A subset (*n*: 9 WT SHAM, 6 mMCP-4 KO SHAM, 7 WT PMI, and 7 mMCP-4 KO PMI) of the 3-day protocol mice underwent positron emission tomography (PET) imaging as described below. The mice were then anesthetized and sacrificed and the hearts and lungs were collected, rinsed with isotonic NaCl (0.9%) to remove blood and put in formalin for histologic measurements or frozen at -80°C for protein analysis. Furthermore, another group of mice was monitored to establish a 4-week survival curve (7 SHAM and 15 PMI animals per genotype), and the surviving mice were sacrificed after completion of the 28-day protocol.

Positron Emission Tomography
----------------------------

Seventy two hours after the induction of myocardial infarction, the mice were anesthetized with isoflurane and a catheter was inserted in the caudal vein to permit intra-venous administration of ^18^F-fluorodeoxyglucose (^18^F-FDG). The mice were then placed on the PET imaging bed with electrodes for electrocardiogram recording (ECG). A 45-min dynamic and synchronized data acquisition sequence in list mode was then launched simultaneously with the administration of ∼5 MBq of ^18^F-FDG in the caudal vein (100 μl infusion in 30 s). Glycaemia was measured before and again at the end of the imaging session, and another blood sample was collected, weighted and measured using a gamma radiation counter to normalize the blood time-activity curve. The mice were then euthanized by CO~2~ inhalation.

Reconstructed PET images were analyzed by tracing regions of interest (ROI) on the viable myocardium, left ventricular blood pool and liver to extract the tissue and blood time-activity curves. The blood input function was derived from the initial blood pool ROI and late liver ROI to overcome the spill-in problem of the left ventricular blood pool by the myocardium in the late portion of the time-activity curve. Pixel counts were corrected for radioactive decay of ^18^F and the counting efficiency of the PET scanner to obtain results in terms of percentage of injected dose per weight of tissue (%ID/g). We used the general solution of the three-compartment kinetic model of FDG to extract the myocardial metabolic rate of glucose (MMRG). Ventricular volumes and ejection fractions were calculated using standard clinical cardiac analysis software packages adapted to preclinical data. Polar maps were constructed by the reorientation of PET data to create a flat round representation of the myocardial external surface, with the apex in the middle as previously described ([@B26]). The infarcted area was then determined as the region with reduced tracer uptake.

Microscopic Morphology Analysis
-------------------------------

Formalin-fixed hearts were embedded in paraffin and 4 μm sections were cut in the short axis with a microtome. Selected sections were then deparaffinized in toluene, rehydrated in ethanol and water, then stained with hematoxylin and eosin (H&E), picrosirius red or toluidine blue ([@B35]). The slides were dehydrated with ethanol and then toluene, mounted with Permount medium (Fisher Scientific, Fair Lawn, NJ, United States) and imaged using a NanoZoomer 2.0-RS digital slide scanner (Hamamatsu Photonics, Hamamatsu, Japan).

Active (cleaved, Asp175) caspase-3 staining was performed using the rabbit anti-mouse active caspase-3 antibody (1:800, catalog \# 9661, Cell Signaling Technology, ON, Canada) for a 30 min, RT incubation, after low pH antigen retrieval (EnVision FLEX Target Antigen Retrieval kit, Agilent, Montreal, QC, Canada). Detection was performed using horseradish peroxidase-linked goat anti-rabbit secondary antibody and revealed with the EnVision FLEX HRP high pH kit (Agilent) using the hydrogen peroxide and 3,3′-diaminobenzidine (DAB) chromophore system, with hematoxylin as counterstain.

Analysis of the images was performed with the NDP.view2 software (Hamamatsu Photonics), which provides direct absolute dimensions, such as area and length. The minimum ventricular free wall thickness was determined at the infarct site. Cross-sectional cardiomyocyte area was determined in the papillary muscle distal to the infarct site as previously described ([@B14]). Major and minor transverse axes and cross-sectional area were measured, and cardiomyocytes with an aspect ratio of ≥1.2 were excluded. This helped eliminate cells sectioned tangentially. Ten cardiomyocytes were measured per mouse heart section, with the average providing the value for the mouse specimen. Furthermore, inflammatory invasion and eosinophilia areas (both signs of cardiomyocyte death) were measured. The inflammatory invasion was defined as areas of nuclei-rich, eosin-poor staining, showing clearing of cardiomyocytes after necrosis and the invasion of multiple leukocytes. Eosinophilia is characterized by nuclei-free, more intensively eosin stained cardiomyocyte regions, showing cells in the process of necrosis. The total calculated area was corrected for the whole left ventricular wall with the NDP.view2 software. Image quantification was performed using ImageJ software.

Proteomics
----------

### Sample Preparation for the LC-MS/MS Glycoproteomic Analysis

Left heart ventricles were reduced to a fine powder in liquid nitrogen using a mortar and a pestle. Soluble proteins were washed away by incubating the heart powder with PBS in the presence of protease inhibitors. Samples were centrifuged and the supernatant was discarded. Insoluble material was partly re-suspended in urea and subsequently re-centrifuged. The supernatant was removed and kept on ice (first solubilisation). The rest of the insoluble material was re-suspended in urea, thiourea and CHAPS, was centrifuged (second solubilisation) and the pellet was discarded. The soluble supernatants were then mixed together. Proteins were reduced with DTT and the total protein content was determined by colorimetry using Pierce 660 protein assay. Proteins were then alkylated with iodoacetamide in the dark, the reaction then quenched with additional DTT. Glycopeptides were oxidized with sodium periodate in the dark. Proteins were then precipitated by adding chilled acetone and the samples were placed at -80°C overnight. Precipitated proteins were aliquoted in several tubes and centrifuged. Pellets were washed twice with acetone:water (6:1) and then pooled and re-solubilized with urea-thiourea-CHAPS and in pH 5 sodium acetate. Glycoproteins were purified by adding hydrazide beads to the samples; unbound proteins were washed away with NaCl and then PBS. Proteins were digested with trypsin and then purified by reversed phase solid phase extraction, dried in a vacuum centrifuge, reconstituted in 0.2% formic acid and analyzed by LC-MS/MS.

### LC-MS/MS Analysis

Acquisition was performed with a SCIEX TripleTOF 5600 (SCIEX, Foster City, CA, United States) equipped with an electrospray interface with a 25 μm iD capillary and coupled to an Eksigent μUHPLC (Eksigent, Redwood City, CA, United States). Analyst TF 1.6 software was used to control the instrument and for data processing and acquisition. Acquisition was performed in information dependant acquisition (IDA) mode for the protein database and in SWATH acquisition mode for the samples. For the SWATH acquisition, variable window sizes were used as computed by the SWATH Variable Window Calculator_V1.0 (SCIEX, Foster City, CA, United States). Separation was performed on a reversed phase HALO C18-ES column (Advance Materials Technology, Wilmington, DE, United States).

### Data Analysis

Protein identification was performed with ProteinPilot V4.5 beta (SCIEX) with the instrument pre-set for TripleTOF5600. The ion libraries used for protein quantification were derived from the protein database generated by the IDA analysis of a pool of all the samples, which was injected twice in the MS. For protein quantification, data was analyzed using the PeakView software (SCIEX). A peptide was considered as adequately measured if the score computed by PeakView was superior to 0.5 or had a false discovery rate (FDR) \< 1. Data is expressed as Log~2~ ratio of mMCP-4 KO/WT.

Enzymatic Assays
----------------

Recombinant mMCP-4 (rmMCP-4) was produced in our facilities and activated with recombinant mouse cathepsin C (R&D Systems, Minneapolis, MN, United States) as previously described ([@B50]). The rmMCP-4 (0.61 and 3.03 ng) was pre-incubated with either PBS or the chymase inhibitor TY-51469 (for a final concentration of 10 μM after substrate addition) at room temperature, then incubated with recombinant mouse IGF-1 (rmIGF-1, 1 μg, Sigma-Aldrich, St-Louis, MO, United States) or Big endothelin-1 (Big ET-1, 2.56 μg, Bachem, Torrance, CA, United States) in 21 μl for 20 min at 37°C. The reaction was stopped with an equal volume of acetonitrile 20% and formic acid 4% in water and the samples were frozen immediately.

Insulin-like growth factor-1 samples were then analyzed by LC-MS while Big ET-1 samples were analyzed by reverse-phase HPLC at 214 nm with a Zorbax DSC-18 column (Agilent Technologies, Montreal, QC, Canada).

Tissue ET-1 Measurement
-----------------------

The lungs and left heart ventricle from WT and mMCP-4 KO mice were collected 1 and 3 days after surgery and frozen at -80°C until further use. On day of measurement, the samples were homogenized and purified as described before ([@B18]). Immunoreactive ET-1 (IR-ET-1) was then measured by ELISA (Quantikine ELISA, R&D Systems, Minneapolis, MN, United States) according to the manufacturer's instructions.

Plasma Brain Natriuretic Peptide (BNP) Measurement
--------------------------------------------------

Blood from WT and mMCP-4 KO mice were collected by right carotid artery catheterization 1 and 3 days after surgery in sodium citrate 3.5%, plasma was prepared by centrifugation at 1000 *g* for 15 min at RT; 4°C, after which the supernatant was collected and then frozen at -80°C until further use. On the day of measurement, the samples were thawed and directly assayed by ELISA for mouse BNP (MyBioSource, San Diego, CA, United States) according to the manufacturer's recommendations.

Statistics
----------

Kaplan-Meier survival analysis was statistically tested with the Mantel-Cox method, PET and enzymatic assay statistical analyses were performed using a 1-way ANOVA followed by a Holms-Šidak post-test with Prism 7.0 software (GraphPad Software, La Jolla, CA, United States). One symbol (^∗^, \#) denotes *P* \< 0.05, two (^∗∗^, \#\#) show that *P* \< 0.01, and three (^∗∗∗^, \#\#\#) show that *P* \< 0.001. Glycoproteomic analysis was performed using Student's *t*-test in Excel (Microsoft Corporation, Redmond, WA, United States) on data validated with the PeakView software.

Results
=======

Mouse Survival
--------------

Permanent myocardial infarction led to 60% mortality in WT mice (**Figure [1A](#F1){ref-type="fig"}**). This mortality occurred in the first week following PMI, starting with one death at day two. In contrast, PMI only induced mortality in one mMCP-4 KO mouse at day nine, significantly less than in their WT congeners (*P* = 0.0014). SHAM surgery did not induce any mortality. Necropsy revealed that cardiac rupture was the cause of death in all 9 WT mice that did not complete the survival study, but no occurrence was found in mMCP-4 KO mice (**Figure [1B](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Mouse heart weight, corrected to tibial bone length (which is independent of mouse fat content and variation due to the procedure), did not differ between genotypes or between mice that survived or died during the 28-day period (**Table [1](#T1){ref-type="table"}**). A difference was observed, however, in mouse body weight change between surviving and dying WT mice, as surviving but not dying WT mice gained weight (*P* \< 0.05). mMCP-4 KO mice that survived did not significantly lose weight. For subsequent experiments, PMI + 72 h was chosen to include all mice in our analyses before mortality events occurred.

![Kaplan-Meier 28-day survival analysis of mouse survival (Mantel-Cox test) **(A)** and incidence of left ventricular free wall rupture events **(B)** following LAD coronary artery ligation **(A)**. PMI: *n* = 15, SHAM: *n* = 7.](fphar-09-00868-g001){#F1}

###### 

Mouse survival and weight changes after PMI.

  Genotype                             WT             mMCP-4 KO                           
  ------------------------------------ -------------- ------------------- --------------- ----------
  Number (rupture at autopsy)          6              9 (9)               14              1 (0)^∗^
  Heart weight/tibial length (mg/mm)   10.39 ± 0.42   11.36 ± 0.42        10.04 ± 0.25    10.27
  Body weight change (g)               1.93 ± 0.86    --3.54 ± 0.57^\#^   --0.50 ± 0.72   --1.90

The absolute value incidence of mortality and ventricular rupture for dead mice (in parentheses) is indicated, along with the heart weight (corrected with tibial length) and the total weight change after surgery.

∗

is vs. WT (rupture, Mantel-Cox test),

\#

is vs. SHAM (one-way ANOVA with multiple comparisons Holms-Šidak post-test).

Cardiac Hemodynamics
--------------------

Three days after ligation, the mice were subjected to ^18^F-FDG PET to evaluate cardiac function (representative images are shown in **Figure [2](#F2){ref-type="fig"}**). **Table [2](#T2){ref-type="table"}** shows that PMI increased the left ventricular end-diastolic volume (LVEDV) in WT mice compared to SHAM. PMI also significantly increased the LVEDV in mMCP-4 KO mice. Moreover, the LVEDV remained significantly lower in infarcted mMCP-4 KO mice compared to their WT congeners, but this was not the case in SHAM animals. Similar changes were observed for the left ventricular end-systolic volume (LVESV), as PMI increased this parameter in WT and mMCP-4 KO, while it remained significantly lower in mMCP-4 KO mice compared to their WT congeners after PMI but not SHAM surgery.

![Representative cardiac PET imaging of mouse hearts after PMI **(A)**. Mouse hearts were imaged 3 days following surgery with ^18^F-FDG, and 3-dimension images were reconstructed. Below each reconstructed image is the ECG-gated left ventricular volume, measured through eight time points of the cardiac cycle (gating frames) for the same mouse. Polar maps of the mouse hearts were calculated, with the apex in the center, for the calculation of the infarcted area **(B)**.](fphar-09-00868-g002){#F2}

###### 

Left ventricular cardiac parameters and heart weight 3 days after surgery.

                                       WT              mMCP-4 KO                              
  ------------------------------------ --------------- ---------------------- --------------- -------------------------
  EDV (μl)                             48.9 ± 5.4      76.7 ± 3.1^\#^\#       38.0 ± 3.8      60.3 ± 4.0^\#^\#,\*\*
  ESV (μl)                             18.2 ± 3.2      49.5 ± 3.5^\#^\#\#     11.1 ± 3.0      32.9 ± 3.2^\#^\#\#,\*\*
  Ejection fraction (%)                65.1 ± 3.7      35.6 ± 2.1^\#^\#\#     73.6 ± 5.1      45.7 ± 3.6^\#^\#\#,\*
  Infarct size (%)                     0               32.2 ± 2.6^\#^\#\#     0               24.1 ± 2.3^\#^\#\#,\*\*
  MMRG (μmol/100g/min)                 112 ± 13        197 ± 17^\#^\#         125 ± 22        136 ± 8
  Heart weight/tibial length (mg/mm)   8.23 ± 0.27     10.73 ± 0.62^\#^\#\#   7.63 ± 0.17     10.06 ± 0.20^\#^\#\#
  Body weight change (g)               --1.86 ± 0.43   --5.17 ± 0.81^\#^\#    --1.73 ± 0.29   --3.51 ± 0.38^\#^

The left ventricular cardiac parameters were taken using

18

F-FDG TEP, 3 days after SHAM surgery or the ligation of the LAD coronary artery, on isoflurane anesthetized mice. Sample size in parenthesis. \# is vs. SHAM,

∗

is vs. WT (One-way ANOVA with multiple selected comparisons Holms-Šidak post-test). EDV, end-diastolic volume; ESV, end-systolic volume; MMRG, myocardial metabolic rate of glucose.

Permanent myocardial infarction significantly reduced the ejection fraction (EF) in WT compared to SHAM operated mice. The mMCP-4 KO mice subjected to PMI exhibited a lower EF than their SHAM counterparts, but preserved their EF significantly better when compared to WT PMI controls.

Cardiac Metabolism and Morphology
---------------------------------

Polar maps derived from ^18^F-FDG PET images (**Figure [2B](#F2){ref-type="fig"}**) were used to evaluate the infarcted area. SHAM surgery did not induce any visible infarction. The infarct area was significantly reduced in mMCP-4 KO compared to WT mice. H&E staining of formalin fixed heart slices showed extensive left ventricular remodeling in WT mice after PMI (**Figure [3](#F3){ref-type="fig"}** and **Supplementary Figure [S1](#SM2){ref-type="supplementary-material"}**). Toluidine blue staining revealed very few traces of mast cells in the myocardium, especially the infarcted area (**Supplementary Figure [S1](#SM2){ref-type="supplementary-material"}**), perhaps due to granule-poor mast cells after degranulation. It did, however, illustrate an increase in invading cells in the infarcted area of WT animals compared to mMCP-4 KO congeners 7 days post-PMI.

![Representative H&E staining of heart sections 3 days following LAD coronary artery ligation **(A)**. § notes eosinophilia sites, ∞ marks inflammatory cell invasion sites. The minimal thickness at the infarct site **(B)**, eosinophilic and inflammatory regions **(C)** and cardiomyocyte cross-sectional area **(D)** were measured from the same images and quantified. (\#: PMI vs. SHAM, ^∗^: mMCP-4 KO vs. WT, one-way ANOVA with multiple comparisons Holms-Šidak post-test).](fphar-09-00868-g003){#F3}

Permanent myocardial infarction induced cardiomyocyte death (characterized by neutrophil invasion and eosinophilia of nuclei-free dying cells) in a similar fashion to the observed infarcted area as seen by ^18^F-FDG PET, although the difference between WT and mMCP-4 KO did not reach statistical significance in infarcted animals. Caspase-3 activation was increased after PMI, reaching a peak after 3 days and subsidizing by day seven (**Figure [4](#F4){ref-type="fig"}**). This increase was localized mainly in the infarcted area, and was more pronounced in WT mice at 3 days compared to their mMCP-4 KO congeners following PMI surgery (WT SHAM 3 days: 2.4 ± 0.4% of total section area, *n* = 8; WT PMI 1 day: 1.5 ± 0.1%, *n* = 8; WT PMI 3 days: 27.9 ± 1.5%, *n* = 12, *P* \< 0.01 vs. WT SHAM 3 days; WT PMI 7 days: 2.5 ± 0.2%, *n* = 7; mMCP-4 KO SHAM 3 days: 4.3 ± 0.6%, *n* = 8; mMCP-4 KO PMI 1 day: 3.1 ± 0.5%, *n* = 6; mMCP-4 KO PMI 3 days: 14.7 ± 1.7%, *n* = 8, *P* \< 0.001 vs. mMCP-4 KO SHAM 3 days, *P* \< 0.001, vs. WT PMI 3 days, *P* \< 0.001; and mMCP-4 KO PMI 7 days: 6.4 ± 0.4%, *n* = 8). Mice subjected to SHAM surgery showed signs of inflammation on the epicardium side of the left ventricular wall, but no cardiomyocyte necrosis inside the myocardium and no difference were noted between WT and mMCP-4 KO mice.

![Representative active caspase-3 **(A)** and collagen deposition **(B)** of heart sections following LAD coronary artery ligation or SHAM surgery. Active caspase-3 DAB (brown) staining \[quantified in **(C)**\] is visible against the hematoxylin (blue) counterstain, while collagen deposition \[quantified in **(D)**\] is marked by the picrosirius red stain. (\#: PMI vs. SHAM, ^∗^: mMCP-4 KO vs. WT, one-way ANOVA with multiple comparisons Holms-Šidak post-test).](fphar-09-00868-g004){#F4}

Three days after surgery, the minimum ventricular free wall thickness did not vary between WT and mMCP-4 KO mice subjected to SHAM surgery (WT SHAM: 1287 ± 88 μm and mMCP-4 KO SHAM: 1394 ± 94 μm, *n* = 5; **Figure [3](#F3){ref-type="fig"}**). PMI reduced the minimum free wall thickness after 3 days in both groups of mice compared to SHAM animals, but it remained significantly higher in mMCP-4 KO mice compared to their WT congeners (WT PMI: 676 ± 42 μm, *P* \< 0.001 vs. WT SHAM; mMCP-4: 1015 ± 93 μm, *P* \< 0.05 vs. mMCP-4 KO SHAM, *P* \< 0.05 vs. WT PMI, *n* = 6). PMI also increased papillary cardiomyocyte cross-sectional area, but there was no difference between WT and mMCP-4 KO. Finally, picrosirius red staining (**Figure [4](#F4){ref-type="fig"}**) revealed that fibrosis in the infarcted area was already visible at 3 days in PMI mice, to reach a maximum at 7 days post-surgery (WT SHAM 7 days: 2.6 ± 0.5% of total section area, *n* = 8; WT PMI 1 day: 0.7 ± 0.04%, *n* = 8; WT PMI 3 days: 8.9 ± 1.2%, *n* = 12, *P* \< 0.05 vs. WT SHAM 3 days; WT PMI 7 days: 19.6 ± 1.8%, *n* = 8; mMCP-4 KO SHAM 7 days: 3.2 ± 0.6%, *n* = 6; mMCP-4 KO PMI 1 day: 0.9 ± 0.1%, *n* = 8; mMCP-4 KO PMI 3 days: 14.2 ± 3.3%, *n* = 7, *P* \< 0.001 vs. mMCP-4 KO SHAM 7 days; and mMCP-4 KO PMI 7 days: 36.3 ± 2.9%, *n* = 8). This increase in collagen deposition tended to be higher in mMCP-4 KO mice (*P* = 0.2) at 3 days post-PMI and reached statistical significance (*P* \< 0.001) at 7 days post-PMI.

^18^F-fluorodeoxyglucose PET analysis also permits the monitoring of cardiac glucose consumption (**Table [2](#T2){ref-type="table"}**). PMI increased MMRG in WT compared to mMCP-4 KO mice. Notably, the glucose consumption in infarcted mMCP-4 KO mouse hearts was similar to that of SHAM.

Heart hypertrophy was visible 3 days after PMI. Heart weight was elevated by PMI in WT compared to SHAM operated mice and mMCP-4 KO mice. There was no difference between WT and mMCP-4 KO mice after either SHAM or PMI surgery. WT mice also lost weight post-surgery, as did mMCP-4 KO mice.

One day post-PMI, plasma BNP levels were not different between WT and mMCP-4 KO mice after SHAM surgery (**Figure [5](#F5){ref-type="fig"}**) (WT SHAM: 65.0 ± 7.3 pg/ml, mMCP-4 KO SHAM: 65.4 ± 10.6 pg/ml, *n* = 6). PMI did not increase plasma BNP levels (WT PMI: 79.6 ± 7.0 pg/ml; mMCP-4 KO PMI: 70.9 ± 13.5 pg/ml, *n* = 6). Similar results were observed 72 h after surgery (WT SHAM: 65.48 ± 8.5 pg/ml; mMCP-4 KO SHAM: 59.6 ± 11.0 pg/ml, *n* = 6; WT PMI: 58.7 ± 7.0 pg/ml; and mMCP-4 KO PMI: 65.3 ± 8.2 pg/ml, *n* = 6). Plasma BNP levels from naïve animals were less than 50% of those from SHAM and PMI operated mice (data not shown), indicating that surgery (SHAM and PMI) increased plasma BNP levels similarly from baseline.

![Plasma levels of BNP 1 or 7 days after SHAM or PMI surgery as measured by ELISA. *n* = 6 (one-way ANOVA *P* \> 0.05).](fphar-09-00868-g005){#F5}

Glycoproteomic Analysis
-----------------------

Glycoproteins were isolated from the left heart ventricles 72 h after PMI and were analyzed using TripleTOF mass spectrometry. A total of 999 glycoproteins were detected in SHAM and PMI mice (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). **Table [3](#T3){ref-type="table"}** shows proteins whose levels were different between WT and mMCP-4 KO left ventricles only after PMI (but not in SHAM). Thirty seven glycoproteins were thus detected to be elevated (positive log~2~ ratio) or diminished (negative log~2~ ratio) in mMCP-4 KO mice compared to WT animals after PMI, with a cut-off of *P* \< 0.05 using Student's *t*-test (*n* = 6) for each protein. The single established chymase substrate for which a change was detected is highlighted in bold. Apolipoprotein A1 (ApoA1) was statistically increased in left ventricles of mMCP-4 KO vs. WT mice (*P* = 0.011). Most glycoproteins in the list are of mitochondrial origin. However, whereas certain mitochondrial proteins were upregulated due to the absence of chymase, others were downregulated. It is therefore not clear as to whether the absence of chymase leads to general effects on mitochondrial integrity. Two cardiac muscle proteins were found to be changed between WT and mMCP-4 KO mice following PMI: the upregulated tropomyosin β chain and the downregulated telethonin.

###### 

Proteins differentially expressed (*P* \< 0.05) in infarcted mMCP-4 KO mice compared to infarcted WT congeners.

  Uniprot access code   Protein name                                                                      Log~2~ ratio
  --------------------- --------------------------------------------------------------------------------- --------------
  MYL1_MOUSE            Myosin light chain 1/3, skeletal muscle isoform (MLC1/MLC3)                       7.56
  B7ZCF1_MOUSE          26S protease regulatory subunit 6A                                                1.65
  A2AIM4_MOUSE          Tropomyosin beta chain                                                            1.39
  G5E850_MOUSE          Cytochrome b-5, isoform CRA_a                                                     1.32
  **APOA1_MOUSE**       **Apolipoprotein A-I (Apo-AI)**                                                   **0.76**
  E9Q5L2_MOUSE          Inter alpha-trypsin inhibitor, heavy chain 4                                      0.69
  ITIH3_MOUSE           Inter-alpha-trypsin inhibitor heavy chain H3                                      0.67
  LMNA_MOUSE            Prelamin-A/C \[cleaved into: lamin-A/C\]                                          0.63
  DHE3_MOUSE            Glutamate dehydrogenase 1, mitochondrial (GDH 1) (EC 1.4.1.3)                     0.60
  CES1D_MOUSE           Carboxylesterase 1D (carboxylesterase 3)                                          0.48
  RL35_MOUSE            60S ribosomal protein L35                                                         0.32
  RL8_MOUSE             60S ribosomal protein L8                                                          0.26
  Q8C2Q8_MOUSE          ATP synthase subunit gamma                                                        0.20
  NDUB9_MOUSE           NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 9 (complex I-B22)     --0.25
  RSSA_MOUSE            40S ribosomal protein SA (37 kDa laminin receptor precursor)                      --0.26
  NDUA1_MOUSE           NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 1 (complex I-MWFE)   --0.27
  KCRS_MOUSE            Creatine kinase *S*-type, mitochondrial (EC 2.7.3.2)                              --0.28
  TELT_MOUSE            Telethonin (titin cap protein)                                                    --0.34
  AT1B1_MOUSE           Sodium/potassium-transporting ATPase subunit beta-1                               --0.36
  RB11B_MOUSE           Ras-related protein Rab-11B                                                       --0.36
  NDUB6_MOUSE           NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 6 (complex I-B17)     --0.37
  PCCA_MOUSE            Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCase subunit alpha)       --0.56
  TBA4A_MOUSE           Tubulin alpha-4A chain (Alpha-tubulin 4)                                          --0.57
  TIM50_MOUSE           Mitochondrial import inner membrane translocase subunit TIM50                     --0.70
  MOES_MOUSE            Moesin (membrane-organizing extension spike protein)                              --0.90
  PGK1_MOUSE            Phosphoglycerate kinase 1 (EC 2.7.2.3)                                            --0.93
  RT4I1_MOUSE           Reticulon-4-interacting protein 1, mitochondrial                                  --1.09
  GSTA4_MOUSE           Glutathione S-transferase A4 (EC 2.5.1.18) (GST A4-4)                             --1.19
  PLP2_MOUSE            Proteolipid protein 2                                                             --1.56
  G5E8T9_MOUSE          Hydroxyacyl glutathione hydrolase (mitochondrial)                                 --1.66
  COQ3_MOUSE            Ubiquinone biosynthesis O-methyltransferase, mitochondrial (EC 2.1.1.114)         --1.69
  DNPEP_MOUSE           Aspartyl aminopeptidase (EC 3.4.11.21)                                            --2.19
  ATAD1_MOUSE           ATPase family AAA domain-containing protein 1 (EC 3.6.1.3) (thorase)              --2.30
  PGAM1_MOUSE           Phosphoglycerate mutase 1                                                         --2.73
  EST1C_MOUSE           Carboxylesterase 1C (EC 3.1.1.1)                                                  --2.78
  E9Q7L0_MOUSE          Protein Ogdhl (oxyglutarate dehydrogenase-like protein)                           --4.06
  RMD1_MOUSE            Regulator of microtubule dynamics protein 1 (RMD-1)                               --7.84

A positive number signifies an increase in mMCP-4 KO mice, while a negative number means a decrease. A chymase substrate, Apolipoprotein A1, is highlighted in bold.

Tissue ET-1 Measurement
-----------------------

One day post-PMI, tissue IR-ET-1 levels were not different between WT and mMCP-4 KO mice after SHAM surgery in either the left heart ventricle (WT SHAM: 0.056 ± 0.012 pg/mg, *n* = 5, mMCP-4 KO SHAM: 0.068 ± 0.011 pg/mg, *n* = 5) or lungs (WT SHAM: 5.21 ± 0.80 pg/mg, *n* = 5 and mMCP-4 KO SHAM: 4.22 ± 0.35 pg/mg, *n* = 5) (**Figure [6](#F6){ref-type="fig"}**). PMI showed a trend to increase left ventricular IR-ET-1 levels in WT mice, but this did not reach statistical significance (WT PMI: 0.111 ± 0.024 pg/mg, *n* = 7). PMI also did not increase IR-ET-1 levels in the mMCP-4 KO left heart ventricle, as it showed no statistically significant differences with SHAM or WT PMI (mMCP-4 KO PMI: 0.089 ± 0.017 pg/mg, *n* = 7). Similar results were obtained 3 days after surgery (WT PMI: 0.102 ± 0.021 pg/mg, *n* = 3; mMCP-4 KO PMI: 0.140 ± 0.022 pg/mg, *n* = 4). However, PMI caused a marked increase in pulmonary IR-ET-1 levels in the lungs of WT mice 1 day after surgery which was abolished in mMCP-4 KO mice (WT PMI: 9.21 ± 0.95 pg/mg, *n* = 7, *P* = 0.0052 vs. WT SHAM and mMCP-4 KO PMI: 5.77 ± 0.58 pg/mg, *n* = 7, *P* = 0.0065 vs. WT PMI). Pulmonary weight did not vary following PMI surgery (WT SHAM 1 day: 5.5 ± 0.1 mg/g body weight, *n* = 7, WT PMI 1 day: 5.5 ± 0.1 mg/g, *n* = 10, WT PMI 3 days: 6.3 ± 0.4 mg/g, *n* = 10, WT PMI 7 days: 6.8 ± 0.7 mg/g, *n* = 11; mMCP-4 KO SHAM: 5.4 ± 0.1 mg/g, *n* = 10; mMCP-4 KO PMI 1 day: 5.8 ± 0.3 mg/g, *n* = 9, mMCP-4 KO PMI 3 days: 6.2 ± 0.2 mg/g, *n* = 10 and mMCP-4 KO PMI 7 days: 6.7 ± 0.3 mg/g, *n* = 10).

![Tissue levels of IR-ET-1 1 day after surgery. The levels of immunoreactive ET-1 were measured in the lungs and left heart ventricle. \#: PMI vs. SHAM, ^∗^: WT vs. mMCP-4 KO, *n* = 5--7, one-way ANOVA with multiple comparisons Holms-Šidak post-test).](fphar-09-00868-g006){#F6}

Enzymatic Assays
----------------

Recombinant mMCP-4 showed rmIGF-1 cleaving activity *in vitro* (**Figure [7A](#F7){ref-type="fig"}**). At 0.61 ng, a quantity previously shown by our group to convert Big ET-1 to ET-1 (1--31) efficiently ([@B50]), rmMCP-4 did not significantly produce the cleaved rmIGF-1 fragment (**Figure [7A](#F7){ref-type="fig"}**) although it processed Big ET-1 to ET-1 (1--31) (**Figure [7C](#F7){ref-type="fig"}**). However, increasing the amount of rmMCP-4 to 3.03 ng led to a significant production of the cleaved IGF-1 peptide but led to an almost complete degradation of Big ET-1 without further increasing detected ET-1 (1--31) levels compared to 0.61 ng. Treatment with TY-51469 (10 μM) completely blocked rmIGF-1 degradation. We also determined that chymase cleaves the Tyr^31^-Gly^32^ bond of mouse IGF-1 (**Figure [7B](#F7){ref-type="fig"}**).

![Analysis of the *in vitro* hydrolysis of recombinant mouse IGF-1 (LC/MS/MS) and Big ET-1 (HPLC) by recombinant mMCP-4, with the chymase inhibitor TY-51469 (10 μM). In **(A)**, the results of recombinant mMCP-4 activity on mouse IGF-1 are shown using trypsin-degradation products, with GFYFNKPTGYGSSIR coming from the complete IGF-1 sequence and GFYFNKPTGY coming from the mMCP-4-cleaved sequence. In **(B)**, the area under the curve (AUC) was measured for Big ET-1 and ET-1 (1--31) using HPLC at 214 nm detection. *n* = 3 (one-way ANOVA with multiple comparisons Holms-Šidak post-test). In **(C)**, the complete sequence of mouse IGF-1 is shown, with the disulfide bonds shown with brackets, the analyzed trypsin-digested product in bold and the cleavage site in increased type size.](fphar-09-00868-g007){#F7}

Discussion
==========

Our study is the first to report the impact of the genetic repression of mMCP-4 in the context of myocardial infarction after permanent LAD coronary artery ligation. This mouse isoform is the closest to human chymase in terms of tissue localization, storage properties and substrate specificity. Thus, mMCP-4 represents a relevant model for the study of the pathophysiological role of chymase in human disease ([@B44]). Our results show that PMI induced a 60% mortality rate in WT mice due to left ventricular free wall thinning and rupture. The wall thinning was reduced in mMCP-4 KO mice, which showed no sign of wall rupture and mortality was almost entirely prevented in the later murine strain. We also show that the repression of mMCP-4 improves cardiac parameters compared to WT mice after PMI, in addition to reducing the infarcted zone, apoptosis signaling and improving energy metabolism. Glycoproteomic analysis of the changes in glycoprotein levels between WT and mMCP-4 KO mice after PMI revealed that ApoA1 was elevated in the left ventricles of mMCP-4 KO mice. Finally, one day after PMI, the levels of ET-1 in the lungs, but not the heart, were elevated in WT but not mMCP-4 KO mice.

Pharmacological inhibition of chymase improves survival in the hamster, rat, and dog after the induction of PMI ([@B22], [@B21], [@B20]; [@B24]). These inhibitors have, however, not been tested for selectivity against mMCP-4 nor against another mouse β-chymase with angiotensinase activity such as mMCP-1. We have previously shown that mMCP-4 deletion reduces chymase-like activity in mouse hearts, while mMCP-1 mRNA levels were unchanged ([@B18]). Thus, the present results suggest for the first time that chymase activity inhibition improves survival in mice following PMI due to impairment of mMCP-4 activity.

Ventricular rupture is a major factor involved in mouse mortality following permanent ligation of the LAD coronary artery ([@B61]; [@B55]). The left ventricular free wall was thinner in WT than mMCP-4 KO mice following PMI, perhaps leading to the observed ventricular wall rupture in those animals. As mMCP-4 can activate numerous matrix degrading enzymes (such as gelatinases) and directly degrades matrix proteins like fibronectin ([@B58], [@B57]), the absence of mMCP-4 may protect the ventricular wall from degradation and rupture. One possible mechanism illustrated in our study is through the increased collagen deposition in the free left ventricular wall. This result is of interest since chymase, through its activation of factors, such as Ang-II, MMP-9, and TGF-β, is reputed to be pro-fibrotic ([@B31]). Although cardiac fibrosis is detrimental to long-term heart function, initial matrix deposition is crucial to the initiation of myocardial repair ([@B9]). The direct effect of chymase on myocardial fibroblasts is less clear, as results from Carver and colleagues suggest that chymase reduces cardiac fibroblast production of extracellular matrix and their conversion to the myofibroblast phenotype, while Hooshdaran and collaborators found that chymase and cathepsin G promote differentiation into myofibroblasts, although they did not differentiate between these two close proteases ([@B4]; [@B15]). Chymase, together with its activation of MMP-9, is also a direct matrix degrading enzyme and may reduce fibroblast pro-collagen-1 production ([@B11]). Therefore, removing chymase from mast cells might protect fibroblast function and the overall pro-fibrotic signals of mast cells ([@B37]), preventing matrix degradation to the point of rupture. Furthermore, chymase promotes apoptosis of smooth muscle cells ([@B7]), and may do so in cardiomyocyte as well ([@B15]). Our results show an increase in active caspase-3 staining in WT mice compared to mMCP-4 KO animals, indicating an increase in apoptosis signaling in cardiomyocytes, albeit our results cannot distinguish cell types outside of the eosinophilic, cardiomyocyte-specific regions. Taken together, these results suggest a protective role for chymase inhibition by reducing ventricular free wall thinning through matrix degradation and apoptosis after PMI.

^18^F-fluorodeoxyglucose PET cardiac analysis has been previously shown in the mouse model to reliably estimate cardiac parameters ([@B53]). To study cardiac function in PMI mice, we chose the 72 h post-PMI mark to include as many mice as possible and to represent the peak of chymase activity following PMI in hamsters ([@B23]). Albeit PMI significantly altered ventricular dilation and ejection fraction in both WT and mMCP-4 KO mice, these changes were less pronounced in the chymase-deficient animals. Similar results were observed with the pharmacological inhibition of chymase in hamsters 3 days post-PMI ([@B21]). Ngkelo and colleagues in contrast, suggested no difference in left ventricular function 14 days after permanent ligation of the LAD coronary artery in mMCP-4 KO mice albeit no supporting data was provided ([@B37]). Thus, chymase activity inhibition appears to protect cardiac function immediately following PMI in rodents, perhaps by limiting remodeling as reflected by our H&E staining. This is in contrast to the ischemia-reperfusion model, where mMCP-4 deletion improves cardiac function no earlier than 14 days post-surgery, reflecting the different pathological development of heart failure in this model ([@B62]; [@B59]). Clearly, there is discrepancy in the data regarding the effect of chymase inhibition on the depression of left ventricular hemodynamic parameters following myocardial infarction.

Compared to other common cardiac imaging techniques such as echocardiography and magnetic resonance imaging, ^18^F-FDG PET loses resolution for hemodynamic and morphologic analyses, but permits infarct size evaluation *in vivo* ([@B54]) as well as glucose consumption measurement ([@B29]; [@B33]). The balance between lipid and glucose consumption by the heart for its energy requirements is shifted from a mostly lipidic to glycemic regime in the infarcted and remodeled regions after myocardial infarction, as glucose consumption is more oxygen-efficient than fatty acid metabolism in the hypoxic tissue ([@B52]). While our imaging study did not consider fatty acid uptake by the mouse heart, glucose consumption was elevated in WT, but not mMCP-4 KO hearts following PMI. This may reflect a greater distress state in WT hearts, as the switch from fatty acid to glucose metabolism may not occur in the very early stages of heart failure and occur later in mMCP-4 KO mice ([@B52]). This is the first study suggesting that chymase inhibition improves the metabolic state of the failing heart, but complementary data such as lipidic metabolism and later time points are needed in future experiments to confirm this activity.

We observed a decreased infarcted zone after PMI in mMCP-4 KO mice compared to their WT congeners. This is in contrast with studies in which pharmacological chymase inhibitors have been used in the hamster after PMI ([@B22], [@B21]; [@B16]). It should be noted that those reports used stacked histochemistry analysis to estimate infarct size. In our study, the decreased infarcted size in mMCP-4 KO did not reach statistical significance in our 2D H&E analysis, while the 3D analysis by ^18^F-FDG PET revealed a similar, but statistically significant, reduction. Thus, methodological differences could explain this discrepancy between our study and the previous reports with chymase inhibitors. Furthermore, chymase inhibition or deletion is able to reduce the infarct size in other models of heart failure, such as ischemia-reperfusion in the swine ([@B42]) or the mouse ([@B59]); this may be due to reduced inflammation-induced cardiomyocyte death when chymase activity is suppressed. The observed beneficiary effects of mMCP-4 deletion on left ventricular dilation and ejection fraction, though statistically significant only in mice subjected to PMI, are similar to those on SHAM animals. Thus, protection of ventricular wall integrity may provide the main mechanism for the promotion of survival by mMCP-4 deletion following PMI, as it is also observed in mice deficient for the ectonucleotidase CD39 ([@B55]) or overexpressing the molecular chaperon melusin ([@B61]). Furthermore, we did not observe significant fibrosis in either WT or mMCP-4 KO mice, suggesting that differences in fibrotic mechanisms do not account in the differences in survival between mouse genotypes.

Few studies measured plasma BNP after myocardial infarction in mice, revealing widely variating results. For instance, Petrera and colleagues measured less than 15 pg/ml in infarcted mice, while Thireau and co-workers measured more than 5 ng/ml in the same model and the same ELISA kit provider ([@B60]; [@B45]). Those studies showed an increase of plasma BNP compared to SHAM animals 4 weeks after the induction of myocardial infarction, but their SHAM surgeries did not involve passing the suture under the LAD coronary artery without ligating. Interestingly, in our study, plasma BNP levels were elevated to the same levels by SHAM and PMI surgery, indicating that, in contrast to clinical settings, this peptide is not a useful biomarker for myocardial infarction severity in mice. It does indicate that our SHAM animals did suffer from a minor infarction, as seen with the histological staining, but without any impact on cardiac function or viability.

In the current glycoproteomic study, well-established chymase substrates went undetected (such as MMP-9) and left ventricular fibronectin (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**) levels did not vary between WT and mMCP-4 KO PMI mice. However, an interesting new identified candidate for cardioprotection in PMI is the chymase substrate ApoA1 ([@B27]). Chymase inhibits ApoA1 cholesterol efflux and anti-inflammatory activity through C-terminal cleavage ([@B32]; [@B41]), which may explain our results even in normolipidemic settings. Furthermore, HDL levels are inversely correlated with percutaneous coronary intervention-related myocardial infarction risks ([@B49]) and ApoA1 plasma levels correlate positively with improved outcomes in coronary artery bypass graft surgery patients, suggesting a protective role in ischemic heart disease ([@B51]). Activation of the receptor for sphingosine-1-phosphate, a HDL component, also reduces infarct size in a pig ischemia-reperfusion model ([@B47], [@B48]). Very recently, [@B25] demonstrated, in a Langendorff-perfused rat heart system, that low flow ischemia induced mast cell degranulation and chymase-like degradation of ApoA1, suggesting a deficiency in endothelial healing processes following myocardial injury. Taken together, our results combined with the literature suggest that chymase inhibition-mediated protection of HDL integrity could explain the lower infarct size after myocardial infarction. Chymase inhibition also protects against cardiomyofibrillar loss in a dog model of mitral regurgitation ([@B43]), a process which may be reflected by the measured increased of tropomyosin β-chain and our histochemical results.

Endothelin-1 is an early protective factor in heart failure *in vivo* and the immediate antagonism of its receptors reduces survival and worsens remodeling in the rat after PMI ([@B38], [@B39]). However, ET-1 is a potent mediator of congestive heart failure-induced pulmonary hypertension ([@B46]), yet pharmacological blockade of endothelin receptors does not improve its parameters in animal models. This suggests that inhibition of ET-1 synthesis by chymase blockade may provide a better pharmacological approach to prevent this complication of PMI ([@B40]; [@B19]), although we did not find evidence of pulmonary inflammation or fibrosis in our model. Since it has no effect on left ventricular levels of ET-1, either after surgery (present study) or endogenously ([@B18]), inhibition of pulmonary located chymase may provide the desired repression of the ET-1 system without impeding its beneficial cardiac effect after PMI. Tejada and colleagues suggested a detrimental role of mMCP-4 in the degradation of IGF-1 during ischemia-reperfusion injury in the mouse ([@B59]). IGF-1, like Big ET-1, possesses potential chymotrypsin-sensitive sites ([@B56]; [@B1]). We found that mMCP-4 cleaves the Tyr^31^-Gly^32^ bond of IGF-1, but very high concentrations of the recombinant enzyme are required to hydrolyze this peptide. Although our results do not rule out a role of mMCP-4 dependent degradation of IGF-1 in our model, we consider unlikely that direct degradation of the growth factor by chymase is responsible for this action *in vivo*.

Ventricular rupture could account to up to 20% of all myocardial infarction related deaths in humans. Reperfusion is the best clinical prevention of this complication, explaining why there are no rupture events in ischemia-reperfusion experimental models where the induced ischemia is comparatively short ([@B8]). Thus, there is a need for more severe disease models such as the permanent ligation of the LAD coronary artery, which is etiologically different from the human clinical situation but more reflective of its outcomes such as ventricular rupture ([@B12]). Our study is the first to report the effect of genetic chymase activity repression on ventricular rupture, joining other recently reported strategies effective in the mouse model ([@B61]; [@B55]). Thus, future studies should establish the impact of pharmacological chymase inhibition on rupture events in the mouse PMI model. The mechanism for cardiac protection due to chymase inhibition also needs to be refined. For example, it would be interesting to determine the role of ApoA1 degradation by chymase, in the context of myocardial infarction.

Conclusion
==========

In conclusion, our results show that chymase repression improves survival and cardiac parameters in a mouse model of PMI. If the present study in the mouse model can be extended to the clinical settings in human subjects, our study suggests that chymase inhibition may be beneficial in the treatment of myocardial infarction.
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^18^F-FDG

:   ^18^F-fluorodeoxyglucose

AMI

:   acute myocardial infarction

ET-1

:   endothelin-1
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:   insulin-like growth factor-1

LAD

:   left anterior descending coronary artery

mMCP-4

:   mouse mast cell protease-4

PET
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:   permanent myocardial infarction

[^1]: Edited by: Colin H. Macphee, GlaxoSmithKline, United States

[^2]: Reviewed by: Paul James White, Monash University, Australia; Claudio de Lucia, Temple University, United States

[^3]: This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
